Peptide Vaccines Enter a New Era: Personalized Cancer Immunization and Neoantigen Breakthroughs

The Promise of Personalized Peptide Vaccines

Peptide-based vaccines are experiencing a renaissance, driven by advances in neoantigen identification, manufacturing speed, and clinical validation across multiple cancer types. The technology, which uses synthetic peptide fragments to train the immune system to recognize and attack specific disease targets, has benefited enormously from the manufacturing and platform innovations catalyzed by the COVID-19 pandemic and is now producing compelling early clinical data in oncology.

The most notable recent result came from Mount Sinai's Icahn School of Medicine, where researchers led by Nina Bhardwaj published Phase 1 data for PGV001, a personalized multi-peptide neoantigen cancer vaccine, in Cancer Discovery in May 2025. The trial treated 13 patients across five tumor types: non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, and multiple myeloma.

PGV001 Results: Durable Responses Across Tumor Types

The results were encouraging for such an early-stage study. PGV001 did not cause serious side effects, with the most common adverse events being mild injection site reactions, fatigue, and fever. At five-year follow-up, six of 13 treated patients survived, and three of those six survivors were tumor-free. The vaccine, using relatively few antigens, was sufficient to induce a strong immune response across multiple cancer types.

The data has prompted three additional PGV001 clinical trials: one in newly diagnosed glioblastoma, one in urothelial cancer in combination with an immune checkpoint inhibitor, and another in prostate cancer. This expansion across diverse tumor types reflects the platform nature of the technology, where the manufacturing process remains consistent while the peptide payload is customized to each patient's unique tumor mutations.

Neoantigen Vaccine Landscape

Beyond Mount Sinai, the neoantigen vaccine space is crowded with competing approaches. The National Cancer Institute lists multiple active clinical trials using neoantigen peptide vaccines across melanoma, breast cancer, lung cancer, and pancreatic cancer. A particularly active area involves combining personalized vaccines with immune checkpoint inhibitors like pembrolizumab, where the vaccine primes tumor-specific T cells that the checkpoint inhibitor then unleashes.

Merck and Moderna's individualized neoantigen therapy, which uses mRNA rather than synthetic peptides, demonstrated in a Phase 2b study that combining their vaccine with pembrolizumab significantly prolonged recurrence-free survival in resected melanoma compared to pembrolizumab alone. While mRNA-based, this program validates the broader neoantigen approach and has raised the profile of all personalized cancer vaccine technologies, including peptide-based platforms.

Peptide vs. mRNA Approaches

The competition between peptide and mRNA vaccine platforms is generating productive scientific debate. Research has shown that vaccines using peptide-pulsed dendritic cells elicit higher per-epitope CD8-positive T cell responses than mRNA-based vaccines, likely due to more efficient class I presentation of synthetic peptides and ex vivo-loaded dendritic cells. However, mRNA vaccines offer faster manufacturing turnaround and the ability to encode multiple antigens in a single construct.

Both approaches benefit from improvements in neoantigen prediction algorithms, which use AI to identify which tumor mutations are most likely to generate immunogenic peptides. The accuracy of these predictions has improved substantially, reducing the number of non-immunogenic peptides included in vaccine formulations and increasing the probability of meaningful immune responses.

Beyond Cancer: Infectious Disease Applications

While oncology dominates the peptide vaccine pipeline, infectious disease applications continue to advance. The COVID-19 pandemic accelerated peptide vaccine technology broadly, and several groups are applying lessons learned to develop next-generation vaccines against influenza, tuberculosis, and emerging viral threats. The stability advantages of synthetic peptides over mRNA, particularly the ability to store them without ultra-cold chain requirements, make them attractive for global health applications.

Outlook

The peptide vaccine field is at an inflection point. The combination of personalized neoantigen targeting, improved manufacturing, AI-driven antigen selection, and positive early clinical data creates a foundation for rapid advancement. While regulatory approval remains several years away for most programs, the trajectory suggests peptide vaccines will become an increasingly important component of precision oncology and immunization strategies.